{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.3","upperLimit":"40.7","value":"18.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Progression was defined using the IMWG criteria.","dispersionType":"Full Range","groups":[{"description":"Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) \\[Car-BiRD\\]\n\nCar Phase:\n\ncarfilzomib: 45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles. Dexamethasone: 20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.\n\nBiRD Phase:\n\nClarithromycin: 500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.\n\nLenalidomide: 25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.\n\nDexamethasone: 40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.\n\nMaintenance Phase:\n\nLenalidomide: 10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.","id":"OG000","title":"Car-BiRD Therapy"}],"paramType":"MEDIAN","populationDescription":"21 participants had an incidence of progression.","reportingStatus":"POSTED","timeFrame":"From start of study drug until first incidence of progression, up to 1222 days.","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}